Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of of HZBio1 in Healthy Subjects
NCT04765995 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2025-05-13
Summary
This randomized study will evaluate the safety, tolerability ,pharmacokinetics, pharmacodynamics and Immunogenicity of single ascending intramuscularly administered doses of HZBio1 in healthy volunteers.
Conditions
- Healthy Participants
Interventions
- DRUG
-
HZBio1 0.96mg / kg
HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
- DRUG
-
HZBio1 3mg / kg
HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
- DRUG
-
HZBio1 6mg / kg
HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
- DRUG
-
HZBio1 9mg / kg
HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
- DRUG
-
HZBio1 12mg / kg
HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
- DRUG
-
Matching placebo will be administered intramuscularly.
Sponsors & Collaborators
-
Peking Union Medical College Hospital
collaborator OTHER -
Hangzhou Grand Biologic Pharmaceutical, Inc.
lead INDUSTRY
Principal Investigators
-
Hongzhong Liu · Peking Union Medical College Hospital
-
Xin Zheng · Peking Union Medical College Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-03-01
- Primary Completion
- 2021-10-31
- Completion
- 2022-01-14
Countries
- China
Study Locations
More Related Trials
-
Phase I Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Injection of SHR-2173 in Healthy Subjects
NCT06995001 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple s.c Doses HS-20004 in Healthy Chinese Volunteers
NCT02746315 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability,PK/PD, Food Effect of Single and Multiple Ascending Doses of HSK31858 in Healthy Volunteers
NCT05663593 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects
NCT04197661 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, and Pharmacokinetics Study of ATH-1020
NCT05169671 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial of HRS-9813 in Healthy Volunteers
NCT06514963 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Administration of HS-10356 in Healthy Volunteers
NCT04652297 ·Status: UNKNOWN ·Phase: PHASE1
-
A Phase I Clinical Trial of JH013 Injection
NCT06633055 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Phase I Study of XH-S002 in Healthy Volunteers
NCT06204419 ·Status: RECRUITING ·Phase: PHASE1
-
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults
NCT06815991 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosed of HSK31858 in Healthy Volunteers
NCT05023525 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Safety,Tolerability,and Pharmacokinetics of Multiple-Ascending Dose JS1-1-01 in Healty Subjects.
NCT05656274 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of HS-10518 in Healthy Adult Premenopausal Females in China
NCT07264192 ·Status: COMPLETED ·Phase: PHASE1
-
Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants
NCT06912295 ·Status: RECRUITING ·Phase: PHASE1
-
Multiple Ascending Dose Study of CM338 in Healthy Volunteers
NCT05371379 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Study of YZJ-4729 Tartrate Injection in Healthy Chinese Subjects
NCT06681493 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ozanimod in Healthy Adult Chinese Subjects
NCT04211558 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-99677 in Healthy Adult Japanese Participants.
NCT04958291 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Study to Evaluate Safety, Tolerability, and Pharmacokinetics of HS-10360 in Healthy Subjects.
NCT04986436 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MHAB5553A in Healthy Volunteers
NCT02528903 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Study of SHR -2001 in Healthy Subjects
NCT05942612 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial of CRB4101 in Healthy Subjects
NCT05641181 ·Status: UNKNOWN ·Phase: PHASE1
-
Single Ascending Dose Study of 9MW3011 in Chinese Healthy Subject
NCT06389942 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled AZD4604 in Healthy Japanese and Chinese Participants.
NCT06519968 ·Status: COMPLETED ·Phase: PHASE1
-
Сlinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of ZE63-0302 in Healthy Volunteers
NCT06780124 ·Status: COMPLETED ·Phase: PHASE1